


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 3691-050510 U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 107524507
INTERNATIONAL APPLICATION NO. PCT/NL2003/000583	INTERNATIONAL FILING DATE 14 August 2003 (14.08.2003)	PRIORITY DATE CLAIMED 14 August 2002 (14.08.2002)
TITLE OF INVENTION USE OF MURINE GENOMIC REGIONS IDENTIFIED TO BE INVOLVED IN TUMOR DEVELOPMENT FOR THE ...		
APPLICANT(S) FOR DO/EO/US Ivo Paul TOUW et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). </p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). </p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. </p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11 to 20 below concern document(s) or information included:		
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A preliminary amendment.</p> <p>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.</p> <p>18. <input checked="" type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input type="checkbox"/> Other items or information:</p>		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER					
107524507		PCT/NL2003/000583		3691-050510					
The following fees have been submitted									
21. <input checked="" type="checkbox"/> Basic national fee.....		\$300		CALCULATIONS PTO USE ONLY					
22. <input checked="" type="checkbox"/> Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4).....		\$100		\$ 300					
All other situations.....		\$200		200					
23. <input checked="" type="checkbox"/> Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority.....		\$100		\$ 400					
International Search Report prepared and provided to the Office.....		\$400		500					
All other situations.....		\$500							
TOTAL OF 21, 22 and 23 = \$ 900									
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.									
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE						
100 - 100 = 0	/50 =		x \$250						
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).									
TOTAL OF ABOVE CACULATIONS = \$ 1,230									
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.									
SUBTOTAL = \$ 615									
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).									
TOTAL NATIONAL FEE = \$ 615									
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property									
TOTAL FEES ENCLOSED = \$ 615									
<table border="1"> <tr> <td>Amount to be refunded:</td> <td>\$</td> </tr> <tr> <td>Amount to be charged:</td> <td>\$</td> </tr> </table>						Amount to be refunded:	\$	Amount to be charged:	\$
Amount to be refunded:	\$								
Amount to be charged:	\$								
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ 615 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0650. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.									
SEND ALL CORRESPONDENCE TO:									
Richard L. Byrne									
Webb Ziesenhein Logsdon Orkin & Hanson, P.C.									
436 Seventh Avenue, 700 Koppers Building									
Pittsburgh, PA 15219-1818									
Telephone: (412) 471-8815									
Facsimile: (412) 471-4094									
									
SIGNATURE									
Richard L. Byrne									
NAME									
28,498									
REGISTRATION NUMBER									

Application No. Not Assigned
Paper Dated: February 14, 2005
In Reply to USPTO Correspondence of N/A
Attorney Docket No. 3691-050510

Customer No. 28289
101524507
DT01 Rec'd PCT/PTC 14 FEB 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : Not Yet Assigned
Applicant : Ivo Paul TOUW et al.
Filed : Concurrently Herewith
Title : USE OF MURINE GENOMIC REGIONS
: IDENTIFIED TO BE INVOLVED IN
: TUMOR DEVELOPMENT FOR THE
: DEVELOPMENT OF ANTI-CANCER
: DRUGS AND DIAGNOSIS OF CANCER
International Application : No. PCT/NL2003/000583
International Filing Date : 14 August 2003
Priority Dates Claimed : 14 August 2002
: 19 September 2002

MAIL STOP PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

LETTER RECOGNIZING ATTORNEYS

Sir:

Enclosed are appropriate papers for initiating the national phase of the above-identified PCT application, comprising a specification, claims, abstract and drawings. A Preliminary Amendment is also enclosed.

Please accept the application for purposes of granting a filing date and recognize Richard L. Byrne, Barbara E. Johnson and Russell D. Orkin, Registration Nos. 28,498, 31,198 and 25,363, respectively, as attorneys in this application, pending the filing of a formal Declaration and Power of Attorney.


Application No. No  Assigned
Paper Dated: February 14, 2005
In Reply to USPTO Correspondence of N/A
Attorney Docket No. 3691-050510

Customer No. 28289

Kindly direct all communications relating to this application to **Richard L. Byrne.**

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.

By 

Richard L. Byrne
Registration No. 28,498
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, Pennsylvania 15219-1818
Telephone: 412-471-8815
Facsimile: 412-471-4094
E-mail: webblaw@webblaw.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

ATTORNEY'S DOCKET NUMBER

Ivo Paul TOUW et al.

3691-050510

PCT/NL2003/000583

ENTITLED

**USE OF MURINE REGIONS IDENTIFIED TO BE INVOLVED IN TUMOR
DEVELOPMENT FOR THE DEVELOPMENT OF ANTI-CANCER DRUGS AND
DIAGNOSIS OF CANCER**

MAIL STOP PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


EXPRESS MAIL CERTIFICATE

"Express Mail" Label Number EV534972785USDate of Deposit February 14, 2005I hereby certify that the following attached paper or fee

Transmittal Letter To The United States
Designated/Elected Office (DO/EO/US) Concerning A
Filing Under 35 U.S.C. 371 (original and two (2) copies)
And Check In The Amount Of \$615.00 For Filing Fee And Surcharge;
Letter Recognizing Attorneys (2 pp.);
Preliminary Amendment; and
WO 2004/016317 Front Page, Specification, Claims, Abstract
Drawings and Search Report (100 pp.)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Susan E. Vresh
(Typed name of person mailing paper or fee)


(Signature of person mailing paper or fee)